These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

367 related items for PubMed ID: 27649365

  • 1. Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study.
    Manzoni P, Paes B, Lanctôt KL, Dall'Agnola A, Mitchell I, Calabrese S, Maule M, Girardi E, Harimoto T, Li A.
    Pediatr Infect Dis J; 2017 Jan; 36(1):2-8. PubMed ID: 27649365
    [Abstract] [Full Text] [Related]

  • 2. Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005-2017.
    Kim D, Saleem M, Paes B, Mitchell I, Lanctôt KL.
    Clin Infect Dis; 2019 Aug 30; 69(6):980-986. PubMed ID: 30517603
    [Abstract] [Full Text] [Related]

  • 3. Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab.
    Paes B, Saleem M, Kim D, Lanctôt KL, Mitchell I.
    Eur J Clin Microbiol Infect Dis; 2019 Aug 30; 38(8):1561-1568. PubMed ID: 31119575
    [Abstract] [Full Text] [Related]

  • 4. Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada.
    Mitchell I, Li A, Bjornson CL, Lanctot KL, Paes BA, CARESS investigators.
    Am J Perinatol; 2022 Nov 30; 39(15):1668-1677. PubMed ID: 33657636
    [Abstract] [Full Text] [Related]

  • 5. Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?
    Bjornson C, Chan P, Li A, Paes B, Lanctôt KL, Mitchell I.
    Eur J Clin Microbiol Infect Dis; 2018 Jun 30; 37(6):1113-1118. PubMed ID: 29557081
    [Abstract] [Full Text] [Related]

  • 6. Comparing First- and Second-year Palivizumab Prophylaxis in Patients With Hemodynamically Significant Congenital Heart Disease in the CARESS Database (2005-2015).
    Li A, Wang DY, Lanctôt KL, Mitchell I, Paes BA, CARESS Investigators.
    Pediatr Infect Dis J; 2017 May 30; 36(5):445-450. PubMed ID: 28403044
    [Abstract] [Full Text] [Related]

  • 7. Restricted Palivizumab Recommendations and the Impact on RSV Hospitalizations among Infants Born at > 29 Weeks of Gestational Age: An Italian Multicenter Study.
    Priante E, Tavella E, Girardi E, Militello MA, Mardegan V, Maule MM, Dall'Agnola A, Baraldi E, Manzoni P.
    Am J Perinatol; 2019 Jul 30; 36(S 02):S77-S82. PubMed ID: 31238365
    [Abstract] [Full Text] [Related]

  • 8. Respiratory Syncytial Virus Prophylaxis in Neurologic and Muscular Disorders in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab.
    Wang DY, Saleem M, Paes BA, Mitchell I, Li A, Lanctôt KL, CARESS Investigators.
    Pediatr Infect Dis J; 2019 Aug 30; 38(8):775-780. PubMed ID: 30985509
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015).
    Wang DY, Li A, Paes B, Mitchell I, Lanctôt KL, CARESS Investigators.
    Eur J Pediatr; 2017 Mar 30; 176(3):413-422. PubMed ID: 28105526
    [Abstract] [Full Text] [Related]

  • 11. Respiratory Syncytial Virus Prophylaxis in Immunocompromised Children: Outcomes From the Canadian RSV Evaluation Study of Palivizumab Registry Over Twelve Seasons (2005-2017).
    Paes BA, Saleem M, Li A, Lanctôt KL, Mitchell I, CARESS Investigators.
    Pediatr Infect Dis J; 2020 Jun 30; 39(6):539-545. PubMed ID: 32235248
    [Abstract] [Full Text] [Related]

  • 12. Respiratory syncytial virus prophylaxis in infants with congenital airway anomalies compared to standard indications and complex medical disorders.
    Paes B, Kim D, Saleem M, Wong S, Mitchell I, Lanctot KL, and the CARESS investigators.
    Eur J Pediatr; 2019 Mar 30; 178(3):377-385. PubMed ID: 30610419
    [Abstract] [Full Text] [Related]

  • 13. Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.
    Forbes ML, Kumar VR, Yogev R, Wu X, Robbie GJ, Ambrose CS.
    Hum Vaccin Immunother; 2014 Mar 30; 10(10):2789-94. PubMed ID: 25483663
    [Abstract] [Full Text] [Related]

  • 14. Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants.
    Rodgers-Gray BS, Fullarton JR, Carbonell-Estrany X, Keary IP, Tarride JÉ, Paes BA.
    J Med Econ; 2023 Mar 30; 26(1):630-643. PubMed ID: 37067826
    [Abstract] [Full Text] [Related]

  • 15. A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age.
    Keary IP, Ravasio R, Fullarton JR, Manzoni P, Lanari M, Paes BA, Carbonell-Estrany X, Baraldi E, Tarride JÉ, Rodgers-Gray B.
    PLoS One; 2023 Mar 30; 18(8):e0289828. PubMed ID: 37561741
    [Abstract] [Full Text] [Related]

  • 16. A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS).
    Paes B, Mitchell I, Li A, Lanctôt KL, CARESS Investigators.
    Eur J Clin Microbiol Infect Dis; 2012 Oct 30; 31(10):2703-11. PubMed ID: 22546928
    [Abstract] [Full Text] [Related]

  • 17. A Comparison of Respiratory Syncytial Viral Prophylaxis in Multiple Births versus Singletons in the Canadian Registry of Palivizumab.
    Paes B, Li A, Kim D, Lanctot KL, Mitchell I, CARESS Investigators.
    Am J Perinatol; 2021 Aug 30; 38(S 01):e129-e136. PubMed ID: 32232817
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020.
    Packnett ER, Winer IH, Larkin H, Oladapo A, Gonzales T, Wojdyla M, Goldstein M, Smith VC.
    Hum Vaccin Immunother; 2022 Nov 30; 18(6):2140533. PubMed ID: 36412253
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.